Michael Klinkenberg

Dr. Michael Klinkenberg

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2010 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
SMSören Mai
Sören Mai
MKMichael Klinkenberg
Michael Klinkenberg
GAGeorg Auburger
Georg Auburger
JBJürgen Bereiter-Hahn
Jürgen Bereiter-Hahn
MJMarina Jendrach
Marina Jendrach
Mitochondria display different morphologies, depending on cell type and physiological situation. In many senescent cell types, an extensive elongation of mitochondria occurs, implying that the increase of mitochondrial length in senescence could have a functional role. To test this hypothesis, human endothelial cells (HUVECs) were aged in vitro. Young HUVECs had tubular mitochondria, whereas senescent cells were characterized by long interconnected mitochondria. The change in mitochondrial morphology was caused by downregulation of the expression of Fis1 and Drp1, two proteins regulating mitochondrial fission. Targeted photodamage of mitochondria induced the formation of reactive oxygen species (ROS), which triggered mitochondrial fragmentation and loss of membrane potential in young cells, whereas senescent cells proved to be resistant. Alterations of the Fis1 and Drp1 expression levels also influenced the expression of the putative serine-threonine kinase PINK1, which is associated with the PARK6 variant of Parkinson's disease. Downregulation of PINK1 or overexpression of a PINK1 mutant (G309D) increased the sensitivity against ROS in young cells. These results indicate that there is a Drp1- and Fis1-induced, and PINK1-mediated protection mechanism in senescent cells, which, when compromised, could contribute to the age-related progression of Parkinson's disease and arteriosclerosis.

12 July 2013 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SGSuzana Gispert
Suzana Gispert
DPDajana Parganlija
Dajana Parganlija
MKMichael Klinkenberg
Michael Klinkenberg
SDStefan Dröse
Stefan Dröse
IWIlka Wittig
Ilka Wittig
GAGeorg Auburger
Georg Auburger
The caseinolytic peptidase P (CLPP) is conserved from bacteria to humans. In the mitochondrial matrix, it multimerizes and forms a macromolecular proteasome-like cylinder together with the chaperone CLPX. In spite of a known relevance for the mitochondrial unfolded protein response, its substrates and tissue-specific roles are unclear in mammals. Recessive CLPP mutations were recently observed in the human Perrault variant of ovarian failure and sensorineural hearing loss. Here, a first characterization of CLPP null mice demonstrated complete female and male infertility and auditory deficits. Disrupted spermatogenesis already at the spermatid stage and ovarian follicular differentiation failure were evident. Reduced pre-/post-natal survival and marked ubiquitous growth retardation contrasted with only light impairment of movement and respiratory activities. Interestingly, the mice showed resistance to ulcerative dermatitis. Systematic expression studies detected up-regulation of other mitochondrial chaperones, accumulation of CLPX and mtDNA as well as inflammatory factors throughout tissues. T-lymphocytes in the spleen were activated. Thus, murine Clpp deletion represents a faithful Perrault model. The disease mechanism probably involves deficient clearance of mitochondrial components and inflammatory tissue destruction.

1 January 2015 in Cell Metabolism
Verified
Journal Article
Closed access
SGStephan Gehrke
Stephan Gehrke
ZWZhihao Wu
Zhihao Wu
MKMichael Klinkenberg
Michael Klinkenberg
YSYaping Sun
Yaping Sun
GAGeorg Auburger
Georg Auburger
BLBingwei Lu
Bingwei Lu

23 December 2016 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
AUAyse Ulusoy
Ayse Ulusoy
RPRobert J. Phillips
Robert J. Phillips
MHMichael Helwig
Michael Helwig
MKMichael Klinkenberg
Michael Klinkenberg
TPTerry L. Powley
Terry L. Powley
DDDonato DiMonte
Donato DiMonte

27 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
EBEun-Jin Bae
Eun-Jin Bae
DKDong-Kyu Kim
Dong-Kyu Kim
CKChangyoun Kim
Changyoun Kim
MMMichael Mante
Michael Mante
AAAnthony Adame
Anthony Adame
SLSeung-Jae Lee
Seung-Jae Lee
Propagation of α-synuclein aggregates has been suggested as a contributing factor in Parkinson’s disease (PD) progression. However, the molecular mechanisms underlying α-synuclein aggregation are not fully understood. Here, we demonstrate in cell culture, nematode, and rodent models of PD that leucine-rich repeat kinase 2 (LRRK2), a PD-linked kinase, modulates α-synuclein propagation in a kinase activity-dependent manner. The PD-linked G2019S mutation in LRRK2, which increases kinase activity, enhances propagation efficiency. Furthermore, we show that the role of LRRK2 in α-synuclein propagation is mediated by RAB35 phosphorylation. Constitutive activation of RAB35 overrides the reduced α-synuclein propagation phenotype inlrk-1mutantC. elegans. Finally, in a mouse model of synucleinopathy, administration of an LRRK2 kinase inhibitor reduced α-synuclein aggregation via enhanced interaction of α-synuclein with the lysosomal degradation pathway. These results suggest that LRRK2-mediated RAB35 phosphorylation is a potential therapeutic target for modifying disease progression.

19 February 2012 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
GAGeorg Auburger
Georg Auburger
MKMichael Klinkenberg
Michael Klinkenberg
JDJessica Drost
Jessica Drost
KMKatrin Marcus
Katrin Marcus
BMBlas Morales-Gordo
Blas Morales-Gordo
MJMarina Jendrach
Marina Jendrach
Parkinson's disease is the second most frequent neurodegenerative disorder. While most cases occur sporadic mutations in a growing number of genes including Parkin (PARK2) and PINK1 (PARK6) have been associated with the disease. Different animal models and cell models like patient skin fibroblasts and recombinant cell lines can be used as model systems for Parkinson's disease. Skin fibroblasts present a system with defined mutations and the cumulative cellular damage of the patients. PINK1 and Parkin genes show relevant expression levels in human fibroblasts and since both genes participate in stress response pathways, we believe fibroblasts advantageous in order to assess, e.g. the effect of stressors. Furthermore, since a bioenergetic deficit underlies early stage Parkinson's disease, while atrophy underlies later stages, the use of primary cells seems preferable over the use of tumor cell lines. The new option to use fibroblast-derived induced pluripotent stem cells redifferentiated into dopaminergic neurons is an additional benefit. However, the use of fibroblast has also some drawbacks. We have investigated PARK6 fibroblasts and they mirror closely the respiratory alterations, the expression profiles, the mitochondrial dynamics pathology and the vulnerability to proteasomal stress that has been documented in other model systems. Fibroblasts from patients with PARK2, PARK6, idiopathic Parkinson's disease, Alzheimer's disease, and spinocerebellar ataxia type 2 demonstrated a distinct and unique mRNA expression pattern of key genes in neurodegeneration. Thus, primary skin fibroblasts are a useful Parkinson's disease model, able to serve as a complement to animal mutants, transformed cell lines and patient tissues.